The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis

Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis

April 1, 2013 • By Anthony S. Russell, MA, MB, BCHIR

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Unsafe at Any Dose


There are two main reasons for arguing against the use of oral steroids in patients with rheumatoid arthritis (RA):

You Might Also Like
  • Oral & Gut Microbiomes Altered in Rheumatoid Arthritis Patients
  • Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
  • Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?
Explore This Issue
April 2013
  1. The risk of developing long-term side effects for relatively little long-term gain.
  2. They are commonly used by nonrheumatologists inappropriately and in excessive dosage; however, the marked short-term symptomatic benefit may delay referral for better long-term treatment.

Why Are Corticosteroids Used?

Recent studies initially by Kirwan and subsequently by several other groups have shown that when initiated alongside disease modifying antirheumatic drug (DMARD) therapy, steroids are associated with a decrease in radiologic progression.1-4 In one longer study, the difference at four years, while statistically significant, was hardly clinically important—a mere four Sharp score units.2 Nevertheless, a DMARD effect exists. In the most recent study, patients with less than one year of RA were treated with a tight control strategy using methotrexate along with 10 mg of prednisone daily (“low dose”).3 At the study completion at the end of two years, there was no observed difference in median Sharp scores, but the percentage of patients with new erosions was statistically different; 78% of those on prednisone and methotrexate were still erosion free compared to 67% on methotrexate alone. The clinical benefit (calculated by DAS28) that was very obvious in the first months of the trial had largely disappeared by the end of the first year of treatment. This is a recurrent theme of studies that use prednisone to treat RA and, despite the radiologic difference observed at two years, Kirwan noted that the clinical effect “did not persist into the second year.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Thus, the rationale for persistent long-term clinical benefit does not seem to hold up when formally tested in a controlled trial rather than using what Dr. Ted Pincus has coined “eminence-based” medicine.

There are no longer-term data beyond four years to say whether the mean four units of Sharp score difference at four years will increase over the next 30 years or remain unchanged. Data from the Better Anti-Rheumatic Farmacotherapy (BARFOT) study observed no change in Sharp scores between Years 1 and 4.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Why Corticosteroids Shouldn’t Be Used

In contrast, we have clear-cut long-term toxicity data to balance against this minor radiologic difference. In 1983, Scott published a 20-year follow-up of RA patients who were receiving steroids along with DMARDs such as gold.5 Many of the patients had become disabled and several had died, with some of deaths thought to be steroid related. In ground-breaking studies, Pincus emphasized the increased mortalities associated with RA and likened it to triple-vessel coronary artery disease or lymphoma.6 He also showed that the mortality rate was increased in those patients receiving steroids versus those who were not (but this is less often emphasized). A study of patients with early RA followed over 15 years found that 39% of those patients who died had been on steroids compared to just 3% of those who were alive.7

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: Oral Corticosteroids, RA, Rheumatoid arthritis, SteroidIssue: April 2013

You Might Also Like:
  • Oral & Gut Microbiomes Altered in Rheumatoid Arthritis Patients
  • Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
  • Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?
  • Letter: No European Consensus on Steroid Use in Rheumatoid Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)